dihexa wiki CAS No : 1401708-83-5 | Product Name : Dihexa | Sigma-Aldrich

Kidney Int Suppl 2000;75:S22S26

Each year, an estimated 300,000 adults in the United States die of causes related to obesity [2] According to the guidelines of the National Institute of Health (NIH) regarding the treatment of obesity, weight loss drugs approved by the FDA [US Food and Drug Administration] may only be used as part of a comprehensive weight loss program, including dietary therapy and physical activity, for patients with a BMI [body mass index] of 30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of 27 with concomitant obesity-related risk factors or diseases[3].The risk factors and diseases considered important enough to warrant pharmacotherapy at a BMI of 27--29.9 are hypertension, dyslipidemia, coronary heart disease (CHD), type 2 diabetes, and sleep apnea [3]

10.2174/1381612824666180608101119 [DOI] [PubMed] [Google Scholar] Sikiric, P

"Leading AI-driven drug discovery platforms: 2025 landscape," ScienceDirect, Nov

Nat Biotechnol 2005

Potential concerns include local injection reactions, immune responses to copper, and theoretical risks from unintended growth pathway activation